Rifabutin


Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. It is typically only used in those who cannot tolerate rifampin such as people with HIV/AIDS on antiretrovirals. For active tuberculosis it is used with other antimycobacterial medications. For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB.
Common side effects include abdominal pain, nausea, rash, headache, and low blood neutrophil levels. Other side effects include muscles pains and uveitis. While no harms have been found during pregnancy it has not been well studied in this population. Rifabutin is in the rifamycin family of medications. It by blocking RNA production in bacteria.
Rifabutin was approved for medical use in the United States in 1992. It is on the World Health Organization's List of Essential Medicines.

Medical uses

Rifabutin is now recommended as first-line treatment for tuberculosis, but rifampicin was used more widely because of its cheaper cost. However, due to the expiration of patents, prices are now similar.
Rifabutin is used in the treatment of Mycobacterium avium complex disease, a bacterial infection most commonly encountered in people with late-stage AIDS. Its main usefulness lies in the fact that it has fewer drug interactions than rifampicin; therefore people with HIV/AIDS on HAART are usually given rifabutin for treatment of TB.
Rifabutin is well tolerated in people with HIV-related tuberculosis, but new findings suggest that with low CD4 cell counts have a high risk of treatment failure or relapse due to acquired rifamycin resistance. Since patients co-infected with TB and HIV/AIDS are likely to get TB treated first, when the CD4 is suppressed at the time TB treatment begins, doctors and patients should be aware of a possible rifamycin resistance.
Rifabutin is also being investigated in trials for treating Crohn's disease as part of the anti-MAP therapy. In a Phase III study administering sub-therapeutic doses of rifabutin in combination therapy to patients not identified with MAP infections, it was associated with significant short term benefits.
It has also found to be useful in the treatment of Chlamydophila pneumoniae infection.

History

Scientists at the Italian drug company Achifar discovered rifabutin in 1975. This company's Adria Laboratories subsidiary filed for Food and Drug Administration approval of rifabutin under the brand name Mycobutin in the early 1990s and the drug gained FDA approval in December 1992.
Rifabutin is primarily bactericidal antibiotic drug used to treat tuberculosis. Its effect on bacteria is based on the DNA-dependent RNA polymerase blocking drug rifamycin S, a semi-synthetic derivative. It is effective, for example, in highly resistant mycobacteria, Gram-positive bacteria, but also against Mycobacterium tuberculosis, M. leprae, and M. avium intracellulare.